GTC
KZR

Ghost Tree Capital’s Kezar Life Sciences KZR Stock Holding History

Ghost Tree Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,500
Closed -$548K – 66
2023
Q1 		$548K Sell
17,500
-16,491
-49% -$954K 0.16% 54
2022
Q4 		$2.39M Sell
33,991
-18,509
-35% -$1.37M 1.02% 27
2022
Q3 		$4.52M Buy
52,500
+7,500
+17% +$729K 1.27% 30
2022
Q2 		$3.72M Buy
45,000
+5,000
+13% +$441K 1.94% 22
2022
Q1 		$6.65M Buy
40,000
+15,000
+60% +$2.15M 1.44% 15
2021
Q4 		$4.18M Buy
+25,000
New +$2.82M 1.5% 27

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ghost Tree Capital's KZR Position: Q2 2023 in Review

Ghost Tree Capital sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 17,500 shares — an estimated $548K sold.

Ghost Tree Capital first reported a position in KZR in Q4 2021 and held it in 6 quarters. The position peaked at $6.65M in Q1 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Ghost Tree Capital reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 17,500 Kezar Life Sciences shares in Q2 2023, an estimated $548K.
  • Ghost Tree Capital first reported a position in Kezar Life Sciences in Q4 2021 and held it in 6 quarters.
  • Ghost Tree Capital's Kezar Life Sciences position peaked at $6.65M in Q1 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.